Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy for dMMR glioma
NL-OMON57655Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in glioma and brain neoplasm, sponsored by Erasmus MC. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
03
Conditions
gliomabrain neoplasm
Beyond the preview
Go deeper on NL-OMON57655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57655.